ReviewTherapeutic advances in gastroenterology2026
All-cause and cause-specific mortality in chronic pancreatitis: A systematic review.
Review in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic pancreatitis (CP) is a progressive fibroinflammatory disease associated with substantial long-term morbidity. Synthesized evidence on mortality remains limited. Objectives: To systematically review all-cause and cause-specific mortality in adults with CP compared with individuals without CP. Design: This systematic review of observational studies adhered to the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines. Data sources and methods: We searched PubMed, Web of Science, Embase, Scopus, and Cochrane Central Register of Controlled Trials from database inception to May 29, 2025. Reference list screening, citation tracking, and targeted author- and consortium-based searches were also conducted. Eligible studies included adults with CP that reported mortality outcomes with a non-CP comparator. Data extraction was conducted by one reviewer while another confirmed accuracy. Quality assessment was done by two independent reviewers and conflicts resolved by a third reviewer. Narrative synthesis was done due to high heterogeneity across studies. Results: Of 11,957 records screened through title and abstract, 347 underwent full-text review, and 12 met inclusion criteria. Four additional studies were found through reference list, citation tracking, and targeted searches, yielding a total of 16 included studies with cohort design. Across seven comparative studies, CP was consistently associated with higher all-cause mortality, with standardized mortality ratios ranging from 1.20 to 5.50 and hazard ratios ranging from 1.25 to 5.00. Malignancy was the most frequently reported cause of death. Other causes included cardiovascular, suicide, infectious, liver-related, gastrointestinal, endocrine, renal, respiratory, and accidental. Conclusion: CP is associated with excess all-cause mortality and a broad cause-specific mortality burden extending beyond pancreas-related complications alone. These findings support recognizing CP as a systemic, high-risk chronic disease and highlight the need for more consistent mortality reporting and better-designed studies to clarify which patients are at highest risk. Registration PROSPERO: CRD420251041174.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.